FNDC5

Fibronectin type III domain-containing protein 5, the precursor of irisin, is a type I transmembrane glycoprotein that is encoded by the FNDC5 gene.^[5][6][7] Irisin is a cleaved version of FNDC5, named after the Greek messenger goddess Iris.^[7]

FNDC5
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 4LSD
Identifiers
Aliases	FNDC5, FRCP2, irisin, Irisin, fibronectin type III domain containing 5
External IDs	OMIM: 611906 MGI: 1917614 HomoloGene: 17812 GeneCards: FNDC5
Gene location (Human) Chr. Chromosome 1 (human)^[1] Band 1p35.1 Start 32,862,268 bp^[1] End 32,872,482 bp^[1]
Gene location (Mouse) Chr. Chromosome 4 (mouse)^[2] Band 4|4 D2.2 Start 129,030,792 bp^[2] End 129,038,386 bp^[2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in vastus lateralis muscle gastrocnemius muscle deltoid muscle tibialis anterior muscle left ventricle body of tongue parotid gland prefrontal cortex cingulate gyrus Brodmann area 9 Top expressed in interventricular septum myocardium of ventricle cerebellar cortex soleus muscle extraocular muscle medial vestibular nucleus superior frontal gyrus digastric muscle cerebellar vermis lateral geniculate nucleus More reference expression data BioGPS n/a
Gene ontology Molecular function hormone activity molecular function Cellular component integral component of membrane extracellular region peroxisomal membrane peroxisome membrane endoplasmic reticulum plasma membrane Biological process response to muscle activity positive regulation of brown fat cell differentiation regulation of signaling receptor activity biological process signal transduction Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 252995 384061 Ensembl ENSG00000160097 ENSMUSG00000001334 UniProt Q8NAU1 Q8K4Z2 RefSeq (mRNA) NM_153756 NM_001171940 NM_001171941 NM_027402 RefSeq (protein) NP_001165411 NP_001165412 NP_715637 NP_081678 Location (UCSC) Chr 1: 32.86 – 32.87 Mb Chr 4: 129.03 – 129.04 Mb PubMed search ^[3] ^[4]
Wikidata
View/Edit Human View/Edit Mouse

Fibronectin domain-containing protein 5 is a membrane protein comprising a short cytoplasmic domain, a transmembrane segment, and an ectodomain consisting of a ~100 kDa fibronectin type III (FNIII) domain.^[8]

History

FNDC5 was first discovered in 2002 during a genome search for fibronectin type III domains^[9] and independently, in a search for peroxisomal proteins.^[5][10]

The ectodomain was proposed to be cleaved to give a soluble peptide hormone named irisin. Separately it was proposed that irisin is secreted from muscle in response to exercise, and may mediate some beneficial effects of exercise in humans and the potential for generating weight loss and blocking diabetes has been suggested.^{[7][11][12][13][14][15][16][17]} Others questioned these findings.^{[5][18][19][20]} A 2021 review highlights new discoveries of irisin in brain function and bone remodeling, but criticizes all studies using commercial antibody assays to measure irisin concentrations. It also raises a question of how an exercise hormone could arise in evolution.^[21] Shortly afterwards, a study using FNDC5 knock-out mice as well as artificial elevation of circulating irisin levels showed that irisin confers beneficial cognitive effects of physical exercise and that it can serve an exercise mimetic in mice. This regulatory system is therefore investigated for potential interventions to improve cognitive function or alleviate Alzheimer's disease.^[22][23][24]

Biosynthesis and secretion

The FNDC5 gene encodes a prohormone, a single-pass type I membrane protein (human, 212 amino acids; mouse and rat, 209 amino acids) that is upregulated by muscular exercise and undergoes post-translational processing to generate irisin. The sequence of the protein includes a signal peptide, a single fibronectin type III domain, and a C-terminal hydrophobic domain that is anchored in the cell membrane.

The production of irisin is similar to the shedding and release of other hormones and hormone-like polypeptides, such as epidermal growth factor and TGF alpha, from transmembrane precursors. After the N-terminal signal peptide is removed, the peptide is proteolytically cleaved from the C-terminal moiety, glycosylated and released as a hormone of 112 amino acids (in human, amino acids 32-143 of the full-length protein; in mouse and rat, amino acids 29-140) that comprises most of the FNIII repeat region. The protease/enzyme responsible for the cleavage of FNDC5 to its secreted form, irisin, has not been identified.^[8]

The sequence of irisin is highly conserved in mammals; the human and murine sequences are identical.^[7] However, the start codon of human FNDC5 is mutated to ATA. This causes human FNDC5 to be potentially expressed in two versions:

• The full-length version with an ATA start, which is transcribed at only 1% the level of other animals with the normal ATG start.
• A severely truncated version beginning at methionine-76 (Met-76). This version has no predicted signal peptide required for transport out of cytoplasm.

A mass spectrometry study reported irisin levels ~3 ng/ml in human plasma, a level on par with other key human hormones, such as insulin. The same study reports that the main form in plasma is the ATA form, as expected for signal peptide presense.^[8] There is no comparable study of irisin levels in other animals.

Function

Exercise causes increased expression in muscle of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1alpha), which is involved in adaptation to exercise. In mice, this causes production of the FNDC5 protein which is cleaved to give a new product irisin.^[7][13] Due to its production through a mechanism initiated by muscular contraction, irisin has been classified as a myokine.^[25]

Tissues

Fat

Based on the findings that FNDC5 induces thermogenin expression in fat cells, overexpression of FNDC5 in the liver of mice prevents diet-induced weight gain, and FNDC5 mRNA levels are elevated in human muscle samples after exercise, it has been proposed that irisin promotes the conversion of white fat to brown fat in humans, which would make it a health-promoting hormone.^[11][12][26] While this proposal has been challenged^[27] by evidence finding FNDC5 is upregulated only in highly active elderly humans,^[18] more recent literature has supported the hypothesis of FNDC5 and irisin having a necessary role in exercise related benefits.^[26][6]

Bones

In mice, irisin is released from skeletal muscle during exercise acts directly on bone by increasing cortical bone mineral density, bone perimeter and polar moment of inertia.^[28] Irisin regulates bone remodeling^[29] and bone metabolism in animal models and humans.^[30]

Cognitive effects

Irisin was shown to be a critical regulator of beneficial cognitive effects of physical exercise in rodents.^[24]

Molecular interactions

FNDC5 is known to interact with various different molecules. In exercise related effects, PGC-1alpha induces FNDC5 gene expression through ERRα availability and that exercise leads to increased transcription of Pgc-1α and Errα, thus increased transcription of Fndc5.^[15] Additionally, FNDC5 is a positive regulator of BDNF expression and can influence BDNF expression in the brain even when peripherally delivered by adenoviral vectors.^[15]

Irisin promotes conversion of white adipose tissue (WAT) to brown adipose tissue (BAT) by increasing UCP1 expression.^[7] A 2016 in vitro study of white and brown fat cell tissue found dose-related upregulation of a protein called UCP1 that contributes to the browning of white fat and found other markers that would indicate that the white cells were browning and that fat cells were more metabolically active. Many of the stem cells became a type of cell that matures into bone. The tissue treated with irisin produced about 40 percent fewer mature fat cells.^[7]

Irisin also interacts with BDNF in terms of regulating its levels in the brain.^[15][31] In a recent study, expression of BDNF in the primary hippocampal nerve cells was observed to decrease as glucose concentration and glucose exposure time increased, or in the diabetic rat conditions. The vitality of these primary hippocampal nerve cells from diabetic rats was markedly decreased when BDNF levels were low but improved following irisin treatment. Thus, irisin was found to positively regulate the expression of BDNF and negatively influence the levels of GHbA1c (human glycated hemoglobin A1c) and AGEs, suggesting that irisin influences cognitive dysfunction in rats with type 2 diabetes by regulating the expression of BDNF and glycometabolism.^[31] It appears that these proteins are connected and related to each other in terms of cardiovascular/metabolic diseases, such as hypertension and diabetes.

See also

• GW 501516

References

1. GRCh38: Ensembl release 89: ENSG00000160097 - Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000001334 - Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Erickson HP (October 2013). "Irisin and FNDC5 in retrospect: An exercise hormone or a transmembrane receptor?". Adipocyte. 2 (4): 289–93. doi:10.4161/adip.26082. PMC 3774709. PMID 24052909.
6. Farrash W, Brook M, Crossland H, Phillips BE, Cegielski J, Wilkinson DJ, et al. (June 2020). "Impacts of rat hindlimb Fndc5/irisin overexpression on muscle and adipose tissue metabolism". American Journal of Physiology. Endocrinology and Metabolism. 318 (6): E943–E955. doi:10.1152/ajpendo.00034.2020. PMC 7311674. PMID 32369414.
7. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. (January 2012). "A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis". Nature. 481 (7382): 463–8. Bibcode:2012Natur.481..463B. doi:10.1038/nature10777. PMC 3522098. PMID 22237023.
8. Jedrychowski MP, Wrann CD, Paulo JA, Gerber KK, Szpyt J, Robinson MM, et al. (October 2015). "Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry". Cell Metabolism. 22 (4): 734–740. doi:10.1016/j.cmet.2015.08.001. PMC 4802359. PMID 26278051.
9. Teufel A, Malik N, Mukhopadhyay M, Westphal H (September 2002). "Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes". Gene. 297 (1–2): 79–83. doi:10.1016/S0378-1119(02)00828-4. PMID 12384288.
10. Ferrer-Martínez A, Ruiz-Lozano P, Chien KR (June 2002). "Mouse PeP: a novel peroxisomal protein linked to myoblast differentiation and development". Developmental Dynamics. 224 (2): 154–67. doi:10.1002/dvdy.10099. PMID 12112469. S2CID 42445530.
11. Courage KH. "Newly Discovered Hormone Boosts Effects of Exercise, Could Help Fend Off Diabetes". Observations. Scientific American. Retrieved January 12, 2012.
12. Park A (April 8, 2009). . Health & Science. Time. Archived from the original on April 11, 2009. Retrieved January 12, 2012.
13. Reynolds G (January 11, 2012). "Exercise Hormone May Fight Obesity and Diabetes". Well. The New York Times. Retrieved January 12, 2012.
14. Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y, et al. (February 2014). "Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling". Diabetes. 63 (2): 514–25. doi:10.2337/db13-1106. PMID 24150604.
15. Wrann CD, White JP, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, et al. (November 2013). "Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway". Cell Metabolism. 18 (5): 649–59. doi:10.1016/j.cmet.2013.09.008. PMC 3980968. PMID 24120943.
16. Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang AH, et al. (July 2012). "Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human". Cell. 150 (2): 366–76. doi:10.1016/j.cell.2012.05.016. PMC 3402601. PMID 22796012.
17. Zhang Y, Xie C, Wang H, Foss RM, Clare M, George EV, et al. (August 2016). "Irisin exerts dual effects on browning and adipogenesis of human white adipocytes". American Journal of Physiology. Endocrinology and Metabolism. 311 (2): E530-41. doi:10.1152/ajpendo.00094.2016. PMID 27436609. S2CID 3433786.
18. Timmons JA, Baar K, Davidsen PK, Atherton PJ (August 2012). "Is irisin a human exercise gene?". Nature. 488 (7413): E9-10, discussion E10-1. Bibcode:2012Natur.488E...9T. doi:10.1038/nature11364. PMID 22932392. S2CID 4415979.
19. Albrecht E, Norheim F, Thiede B, Holen T, Ohashi T, Schering L, et al. (March 2015). "Irisin - a myth rather than an exercise-inducible myokine". Scientific Reports. 5: 8889. Bibcode:2015NatSR...5E8889A. doi:10.1038/srep08889. PMC 4352853. PMID 25749243.
20. Raschke S, Elsen M, Gassenhuber H, Sommerfeld M, Schwahn U, Brockmann B, et al. (2013). López-Lluch G (ed.). "Evidence against a beneficial effect of irisin in humans". PLOS One. 8 (9): e73680. Bibcode:2013PLoSO...873680R. doi:10.1371/journal.pone.0073680. PMC 3770677. PMID 24040023.
21. Maak, S.; Norheim, F.; Drevon, C. A.; Erickson, H. P. (2021). "Progress and Challenges in the Biology of FNDC5 and Irisin". Endocrine Reviews. 42 (4): 436–456. doi:10.1210/endrev/bnab003. PMC 8284618. PMID 33493316.
22. "The hormone irisin is found to confer benefits of exercise on cognitive function". medicalxpress.com. Retrieved September 21, 2021.
23. Reynolds, Gretchen (August 25, 2021). "How Exercise May Help Keep Our Memory Sharp". The New York Times. Retrieved September 21, 2021.
24. Islam, Mohammad R.; Valaris, Sophia; Young, Michael F.; Haley, Erin B.; Luo, Renhao; Bond, Sabrina F.; Mazuera, Sofia; Kitchen, Robert R.; Caldarone, Barbara J.; Bettio, Luis E. B.; Christie, Brian R.; Schmider, Angela B.; Soberman, Roy J.; Besnard, Antoine; Jedrychowski, Mark P.; Kim, Hyeonwoo; Tu, Hua; Kim, Eunhee; Choi, Se Hoon; Tanzi, Rudolph E.; Spiegelman, Bruce M.; Wrann, Christiane D. (August 2021). "Exercise hormone irisin is a critical regulator of cognitive function". Nature Metabolism. 3 (8): 1058–1070. doi:10.1038/s42255-021-00438-z. ISSN 2522-5812. PMC 10317538. PMID 34417591. S2CID 237254736.
25. Pedersen BK, Febbraio MA (October 2008). "Muscle as an endocrine organ: focus on muscle-derived interleukin-6". Physiological Reviews. 88 (4): 1379–406. doi:10.1152/physrev.90100.2007. PMID 18923185.
26. Xiong Y, Wu Z, Zhang B, Wang C, Mao F, Liu X, et al. (May 2019). "Fndc5 loss-of-function attenuates exercise-induced browning of white adipose tissue in mice". The FASEB Journal. 33 (5): 5876–5886. doi:10.1096/fj.201801754RR. PMID 30721625. S2CID 73444056.
27. Servick K (March 2015). "Biomedicine. Woes for 'exercise hormone'". Science. 347 (6228): 1299. doi:10.1126/science.347.6228.1299. PMID 25792309.
28. Colaianni G, Cuscito C, Mongelli T, Pignataro P, Buccoliero C, Liu P, et al. (September 2015). "The myokine irisin increases cortical bone mass". Proceedings of the National Academy of Sciences of the United States of America. 112 (39): 12157–62. Bibcode:2015PNAS..11212157C. doi:10.1073/pnas.1516622112. PMC 4593131. PMID 26374841.
29. Kim H, Wrann CD, Jedrychowski M, Vidoni S, Kitase Y, Nagano K, et al. (December 2018). "Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors". Cell. 175 (7): 1756–1768.e17. doi:10.1530/ey.16.15.15. PMC 6298040. PMID 30550785.
30. Colaianni G, Sanesi L, Storlino G, Brunetti G, Colucci S, Grano M (May 2019). "Irisin and Bone: From Preclinical Studies to the Evaluation of Its Circulating Levels in Different Populations of Human Subjects". Cells. 8 (5): 451. doi:10.3390/cells8050451. PMC 6562988. PMID 31091695.
31. Huang L, Yan S, Luo L, Yang L (February 2019). "Irisin regulates the expression of BDNF and glycometabolism in diabetic rats". Molecular Medicine Reports. 19 (2): 1074–1082. doi:10.3892/mmr.2018.9743. PMC 6323232. PMID 30569121.